Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC

The goal of this clinical research study is to add the anti-diabetic drug metformin to standard treatment for lung cancer (radiation therapy and chemotherapy) is more effective than standard treatment alone. The addition of metformin to the usual radiation and chemotherapy could shrink your cancer more than the usual radiation and chemotherapy alone and help prevent it from returning, but it could also cause side effects. This study will allow the researchers to know whether adding metformin to radiation and chemotherapy is better, the same, or worse than radiation and chemotherapy alone. Metformin is already FDA-approved for use in diabetes, and studies have shown that it is safe for use in non-diabetic patients. There will be about 168 people taking part in this study.

Treatment Location: N/A

Sponsor: N/A

IRB Review and Approval Date: 10/22/2015

Recruitment Status: Closed

Projected Accrual: N/A

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT02186847